ArticleOPEN ACCESS

Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial(Nature Medicine, 10.1038/s41591-023-02572-5)

Nature Medicine
DOI: 10.1038/s41591-024-03053-z
1Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-023-02572-5, published online 14 September 2023 In the version of the article initially published, the affiliation of Yassine Al Tabaa was incomplete and has now been updated to read “Scintidoc Nuclear Medicine Center, Clinique Clémentville, Montpellier, France” in the HTML and PDF versions of the article.

Cite

CITATION STYLE

APA

Houot, R., Bachy, E., Cartron, G., Gros, F. X., Morschhauser, F., Oberic, L., … Lemonnier, F. (2024, July 1). Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial(Nature Medicine, 10.1038/s41591-023-02572-5). Nature Medicine. Nature Research. https://doi.org/10.1038/s41591-024-03053-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free